Zydus and its unit will also pay an upfront per-unit license fee for sales of its generic Mirabegron in the US from the date of the agreement until September 2027 | Photo: X@ZydusUniverse
Zydus and its unit will also pay an upfront per-unit license fee for sales of its generic Mirabegron in the US from the date of the agreement until September 2027, the company said.
The deal will allow the company to continue marketing its generic Mirabegron in the United States, Zydus said, adding that other terms of the agreement are confidential.
The announcement comes days after local peer Lupine decided to settle its dispute with Astellas over the same drug for $90 million.
At the time, analysts at brokerage Citi said the development could delay the entry of other generic rivals into the US market, potentially giving Zydus and Lupine a period of limited competition.
(Only the headline and image of this report may have been reworked by Business Standard staff; the rest of the content is automatically generated from a syndicated feed.)
First publication: February 12, 2026 | 9:57 am IS
#Zydus #agrees #pay #million #settle #patent #dispute #Astellas